Trial Profile

A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mecbotamab vedotin (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Bone cancer; Malignant fibrous histiocytoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions; First in man; Registrational; Therapeutic Use
Sponsors BioAtla

15 Jun 2025 Planned End Date changed from 1 Jan 2025 to 30 Jun 2025.
15 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Jan 2025.
15 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com